Best Alpha-Lipoic Acid Supplement: What Actually Matters on the Label

The short answer

Alpha-lipoic acid is one of the few supplement aisles where the expensive-looking option is frequently the worse buy. The premium shelf is full of bottles labelled “R-ALA,” sold on the true claim that R is the natural, better-absorbed enantiomer. What the label usually does not say is that free R-lipoic acid is chemically unstable. It polymerizes, especially with warmth and time, and the polymerized material does not absorb well. So a bottle of plain R-ALA can deliver less usable lipoic acid than the cheap racemic capsule sitting next to it.

That makes the buying decision unusually concrete. You want a stated form (racemic, or a stabilized salt such as sodium R-lipoate), a 600 mg unit if you are matching what the clinical trials used, and a lot-matched third-party certificate of analysis. Skip the proprietary “absorption blends,” and be skeptical of any R-ALA product that will not name its salt form. For the mechanism and evidence behind the compound, start with the alpha-lipoic acid pillar.

The three forms you will actually see

Almost every product on the shelf is one of three things, and the labels are not always candid about which.

Racemic alpha-lipoic acid (R/S-ALA). A 50/50 mix of the R and S enantiomers, produced by ordinary chemical synthesis. This is the cheap, standard, unglamorous option, and it is also the form used in essentially every major clinical trial, including SYDNEY 2 and the four-year NATHAN 1 study. When research says “600 mg of alpha-lipoic acid,” it almost always means this.

Free R-lipoic acid (R-ALA, R-LA). The single natural enantiomer, isolated. Biologically it is the right molecule: in humans given racemic ALA, peak plasma concentrations of the R form run roughly 40 to 50 percent higher than the S form, which is a genuine absorption advantage for R. The catch is stability. Free R-lipoic acid has poor aqueous solubility and a strong tendency to polymerize, and a polymerized capsule is not the thing you paid for.

Stabilized R-lipoate salts (sodium R-lipoate, NaRALA). Converting R-lipoic acid to its sodium salt fixes both the stability and the solubility problem. In the pharmacokinetic work by Carlson and colleagues, 600 mg of sodium R-lipoate produced a mean peak plasma concentration of about 16 µg/mL with a median time to peak of roughly 15 minutes, against figures near 1 µg/mL for the free acid in the paired comparisons. That is a large difference, and it is the reason the salt exists.

⚠ CLAIM (wellness): Stabilized sodium R-lipoate reaches substantially higher peak plasma concentrations than free R-lipoic acid, and R absorbs better than S from racemic material. This is pharmacokinetic data (blood levels), not evidence of better clinical outcomes, which has not been demonstrated. Basis: Carlson 2007; Hermann enantioselective PK. Lane: educational.

One honesty note on that Carlson data, because it matters: the study was small, published in Alternative Medicine Review, and connected to a commercial developer of sodium R-lipoate. The direction of the finding is consistent with the underlying chemistry, and free R-lipoic acid’s instability is not controversial. But treat the exact multiples as a manufacturer-adjacent figure rather than a settled number, and note that no trial has shown the salt produces better clinical results, only better blood levels.

Form	What it is	Case for	Case against
Racemic ALA (R/S)	50/50 synthetic mix	Cheap, stable, and the form the trials actually used	Half the dose is the S enantiomer, which absorbs less well
Free R-ALA	Isolated natural enantiomer	Correct molecule, better absorbed than S	Polymerizes and loses solubility; premium price for a fragile product
Sodium R-lipoate	Salt of the R form	Stable and rapidly absorbed to high plasma peaks	Most expensive; no outcome trials; often sold as a liquid or in blends

Why 600 mg is the number on the label

The 600 mg unit is not marketing convention, it is trial inheritance. SYDNEY 2 randomized patients to 600, 1,200, or 1,800 mg of oral ALA daily for five weeks. All three doses beat placebo on symptom scores, and they beat it by almost exactly the same amount. What did rise with dose was nausea, vomiting, and vertigo. The authors concluded that 600 mg once daily gave the best risk-to-benefit ratio, and that figure has anchored the category ever since. In Germany, thioctic acid at 600 mg is an approved prescription medicine rather than a supplement.

The practical consequence for shopping is simple. A capsule delivering 600 mg of racemic ALA is one trial-equivalent unit. If a product gives you 300 mg, you are taking two. If a product gives you 100 mg of R-ALA and implies it equals 600 mg of racemic material, that is an inference the evidence does not support, because the trials that generated the 600 mg figure did not use R-ALA. We cover the dose and timing question properly in how much alpha-lipoic acid per day.

The unit trap: milligrams of what

This is the single most common way ALA labels mislead, and it takes two forms.

The first is the R-equivalence claim above. There is no validated conversion factor between milligrams of R-ALA and milligrams of racemic ALA in terms of clinical effect, so a label implying one is inventing arithmetic.

The second is salt weight. Sodium R-lipoate is heavier than R-lipoic acid because of the sodium, so a stated milligram figure for the salt contains less lipoate than the same figure for the free acid. A transparent label tells you which it is measuring. A vague one lets you assume the more flattering reading. If a bottle says “R-ALA 300 mg” and elsewhere mentions sodium, ask what the 300 mg refers to. This is the same class of problem we documented with glucoraphanin and sulforaphane in the sulforaphane buying guide.

Third-party testing, and why it is not optional here

Every supplement guide says buy third-party tested. With alpha-lipoic acid there is a specific, concrete reason rather than a generic one: the failure mode is degradation, not adulteration. Nobody has much incentive to cut a cheap synthetic molecule with something else. But R-lipoic acid polymerizes on the shelf, and polymerized ALA still weighs the same. A potency assay on the finished product, on your lot, is the only thing that distinguishes an intact capsule from an expensive one full of polymer.

That puts ALA in the same category as astaxanthin, where we have made the same argument about oxidation: for actives that degrade, a certificate of analysis dated to the raw material tells you what the powder was like before it sat in a warehouse, not what is in your bottle now. Ask for four things.

• Identity and assay on the finished lot, matched to the lot code printed on your bottle, not the raw-material supplier’s document.
• Enantiomeric purity if you are paying for an R product. This is the only way to confirm you did not buy racemic material at an R price, and a company selling R-ALA should have it.
• Heavy metals screening, the standard baseline for any synthesized bulk ingredient.
• A real expiry date and storage guidance. For a compound that polymerizes with heat, “store in a cool dry place” is not boilerplate, it is the instruction.

Capsules, tablets, and what enteric coating is for

Alpha-lipoic acid is a weak acid with poor gastric stability, and its absolute oral bioavailability is only around 30 percent, largely because the liver extracts much of it on the first pass. Plasma levels peak within about an hour and fall quickly.

Enteric coating and delayed-release formats are a reasonable answer to the gastric-stability half of that problem, and they also reduce the mild stomach upset some people get. What they cannot fix is first-pass hepatic extraction, which is most of the story. So treat delayed release as a tolerability feature with a plausible absorption benefit, not as a transformation. Liquid and sublingual sodium R-lipoate products make a stronger absorption argument, backed by the pharmacokinetic data above, at a meaningfully higher price.

Softgels deserve one warning. ALA is often bundled into oil-based softgels alongside other ingredients, and combination products are where dosing clarity goes to die. If the panel shows a proprietary blend with a single total milligram figure, you cannot know how much ALA you are getting, which makes the 600 mg reference point useless.

What a sensible purchase looks like

For most people the honest recommendation is the boring one: plain racemic alpha-lipoic acid at 600 mg per capsule, single ingredient, from a company that publishes a lot-matched third-party COA. It is inexpensive, it is stable, and it is the material the clinical evidence was actually built on. That last point carries more weight than the enantiomer argument, because the enantiomer argument is about blood levels and the trials are about outcomes.

Buy an R product only if it is a named stabilized salt, most commonly sodium R-lipoate, and only if the label is explicit about what the milligrams measure. Paying a premium for free, unstabilized R-ALA is the one clearly poor decision in this category. And if a product is a blend with unspecified amounts, put it back regardless of which form it claims.

Keep the spending proportionate to the evidence. ALA has a real mechanism, a genuine prescription-grade track record in one specific clinical use, and modest results almost everywhere else. It belongs in the well-studied but narrowly-proven tier of our evidence-graded supplement guide, not the foundation tier. It pairs conceptually with acetyl-L-carnitine, though that pairing’s best evidence remains animal work.

Quick label check

What to check	Green flag	Red flag
Form	“Racemic alpha-lipoic acid” or a named salt like sodium R-lipoate	“R-ALA” with no salt named, or no form stated at all
Dose	600 mg per capsule, or a clean fraction of it	An odd figure implying equivalence to a larger racemic dose
Ingredient list	Single ingredient	Proprietary blend with one combined milligram total
Testing	Lot-matched COA: identity, assay, heavy metals	“Lab tested” with no accessible document
Enantiomeric purity	Reported, if you are paying for an R form	R claimed, never verified
Storage and expiry	Real expiry date plus cool, dry storage guidance	No date, or a date on the bottling rather than the contents
Claims	Plain description of the ingredient	Neuropathy, blood sugar, or weight-loss claims on the front

One safety point that changes how you shop

Alpha-lipoic acid is associated with insulin autoimmune syndrome, a rare condition in which the body produces antibodies against its own insulin and causes hypoglycemia. Reviewing 49 published cases, EFSA noted a strong genetic component, tied to specific HLA-DRB1 alleles, and took the view that because the reaction is immunological, dose is probably not the deciding factor.

⚠ CLAIM (wellness-guidance): Alpha-lipoic acid supplementation has been linked to insulin autoimmune syndrome in genetically susceptible people, and the risk does not appear to be simply dose-dependent. Anyone who experiences unexplained hypoglycemia while taking ALA should stop and see a clinician. Basis: EFSA 2021 opinion; Bresciani 2018; Furlanetto 2011 case reports. Lane: wellness-guidance.

The shopping implication is that “start with a low dose to be safe” does not manage this particular risk the way it manages, say, nausea. It is a reason to be deliberate about whether you take ALA at all, especially alongside diabetes medication, rather than a reason to buy a smaller capsule. Separately, and importantly for anyone with a household: accidental ingestion by young children has caused seizures, status epilepticus, and deaths in published case reports. Keep it in a child-resistant container, out of reach.

Educational information only, not medical advice, and not evaluated by the FDA. Alpha-lipoic acid is not a treatment for any disease, and nothing here is a dosing protocol. We do not sell supplements and this guide names no brands. Talk to a clinician before supplementing, particularly if you take diabetes medication or insulin, have thyroid disease, are pregnant or breastfeeding, or have a history of hypoglycemia.